Purpose: Screening of asymptomatic men with prostate specific antigen (PSA) remains a controversial issue. There is limited evidence that screening is effective in reducing mortality from prostate cancer. In the current study we determined if screening with PSA reduces the risk of metastatic prostate cancer.
Prostate cancer is the most frequently diagnosed cancer in North American men and the second leading cause of death due to cancer in men. 1 The epidemiology of prostate cancer has been changed by the introduction of the prostate specific antigen (PSA) in the late 1980s. 2 The PSA test is used as a screening test, a diagnostic tool and a biological marker to follow the progress of disease in patients with prostate cancer. Because of widespread use of PSA for opportunistic screening, the incidence of prostate cancer in the United States and many other countries increased dramatically in the early 1990s. 3 There has also been a shift toward earlier stages at diagnosis. 2, 3 Whether regular PSA measurements should be performed in asymptomatic men remains a controversial issue. There is little evidence to date that screening with PSA is effective in reducing mortality from prostate cancer. A recent casecontrol study in the US showed a benefit from combined digital rectal examination (DRE) and PSA screening but the data were insufficient to assess the effect of PSA alone. 4 Several ecological analyses of population data from the United States and other countries failed to demonstrate a correlation between screening and death rates from prostate cancer 5Ϫ8 , while a study in Austria found a significant association. 9 A randomized trial of PSA screening was conducted in Quebec but the results are difficult to interpret because of a low screening rate in the intervention arm. 10 Two major randomized trials of screening effectiveness are in progress, 1 in the United States and 1 in Europe, but their results will not be available for several years. 11 Given the current controversy regarding the effectiveness of PSA, we conducted a population based case-control study to determine if screening asymptomatic men with PSA reduces the risk of metastatic prostate cancer. Metastatic prostate cancer has a poor prognosis and death from prostate cancer is almost always caused by distant metastases. If screening is effective, we would expect a reduction in metastatic prostate cancer risk before a reduction in mortality. Also, the effect on metastatic prostate cancer should not be confounded by recent improvements in the management of advanced disease.
METHODS
Data collection. The study population included residents of Metropolitan Toronto and 5 surrounding counties in Ontario, Canada. Cases were men who developed metastatic prostate cancer between August 1, 1999 and May 31, 2002. They had to be between 40 and 84 years old when diagnosed with metastatic prostate cancer, diagnosed with prostate cancer on or after January 1, 1990, living in the study area at the time of prostate cancer diagnosis and able to answer a questionnaire in English. We identified new cases of metastatic prostate cancer by monthly searching of computerized lists of prostate cancer patients treated at 2 Regional Cancer Centers serving the study population and by regular monthly contacts by telephone, mail, or email with the urologists and oncologists in the study area who would normally treat men with metastatic prostate cancer. Controls were men without metastatic prostate cancer selected randomly from the municipal tax records database for the study area. Men diagnosed with nonmetastatic prostate cancer were eligible. The controls were sampled throughout the period of case accrual and frequency matched to the cases for age (5-year intervals) and area of residence (8 areas) . In addition, they had to live in the same area as the cases at the time of prostate cancer diagnosis and be able to answer a questionnaire in English. We selected approximately 2 controls for each case. For the purpose of data collection and analysis, each control was assigned a reference date corresponding to the date of prostate cancer diagnosis in a case from the same area and age group.
Self-reported data were obtained on age, ethnicity, marital status, education, income, height, weight, employment history, exposure to certain occupational carcinogens, smoking, alcohol use, history of physical activity, diet, vitamin supplementation, vasectomy, sexual activity, family history of cancer, comorbid conditions, use of health services, urinary symptoms, prostate related tests and procedures and history of PSA testing. We reviewed each participant's medical records obtained from his family physician and, if appropriate, 1 or more specialists. Information was collected on PSA history, genitourinary symptoms, history of benign prostatic hyperplasia (BPH) and treatment, digital rectal and transrectal ultrasound examinations, previous prostate biopsies, major surgical procedures, second cancers, and other comorbidity. The charts were reviewed by experienced and trained data abstractors. In most cases the abstractors were blinded to the case-control status of the subject. We performed an inter-abstractor reliability sub-study on a sample of 88 charts. The reason for each PSA test and the results of digital rectal examinations were determined independently by 2 of the investigators (PSB and JN).
Exposure was defined as having a screening (nondiagnostic) PSA test. We excluded all tests performed after the diagnosis of prostate cancer or the corresponding reference date for the controls. We also excluded PSA tests where there was evidence in the chart that the physician ordering the test suspected prostate cancer. Furthermore, we excluded tests performed after a positive or suspicious digital rectal examination for prostate cancer or a transrectal ultrasound, a repeat of a previous PSA test and all tests following a positive or suspicious imaging study (bone scan, computerized tomography or x-ray) for metastatic cancer. We also excluded PSA tests performed after the subject reported frequent daytime urination, post-void dribbling, hesitancy, incomplete emptying of bladder, intermittent stream, urgency, weak stream, dysuria, nocturia, hematuria, hemospermia, other genital or urinary symptoms, or bone pain. Although such symptoms do not necessarily indicate prostate cancer, the exclusion of tests performed in symptomatic men reduced the possibility of erroneously counting diagnostic tests as screening. All subjects signed a consent form for participation in the study.
The study was approved by the University of Toronto Ethics Review Board and by the ethics review boards of the participating hospitals.
Data analysis. Cases and controls were initially compared in univariate analyses with respect to sociodemographic variables, prostate cancer risk factors, frequency of urinary symptoms, frequency of DRE and health usage variables. In the analysis of PSA screening it was necessary to control for exposure observation time. We analyzed the frequency of PSA screening among cases and controls in a life table constructed with 2-year intervals starting in 1990. Subjects whose observation time ended in a given interval without a PSA test (for example, because they developed urinary symptoms or had a positive DRE) were treated as censored observations. We used the propensity score method to control for other confounding variables. 12 The propensity score was obtained from a multiple logistic regression model. Several variables were associated with case-control status at ␣ ϭ 0.10 and were retained in the model, namely age, region, family history of prostate cancer, weight, consumption of butter and doctor visits for health problems. The score was divided into tertiles and used as a stratification variable. As a measure of effect, we calculated the stratified Mantel-Haenszel odds ratio with test based confidence limits. 13 Results were obtained for the full sample and for 2 age groups, 45 to 59 and 60 to 84 years old. We conducted a sensitivity analysis to assess the effect of excluding PSA tests in men who had a positive or suspicious DRE. All analyses were done with SAS®.
RESULTS
Data were obtained for 236 cases and 462 controls. The average age at prostate cancer diagnosis among the cases was 68.2 years and the average age at metastatic prostate cancer diagnosis was 71.5 years. Distant metastases were detected by bone scan in 72.1% of the cases. Other methods included computerized tomography (12.7%), x-ray (4.6%), magnetic resonance imaging (4.1%), bone biopsy (4.1%) and other techniques (2.4%).
In univariate analysis, no significant differences between the cases and controls were seen with respect to socioeconomic status, immigrant status, most dietary factors, recreational and work related activities, frequency of BPH, or frequency of DREs (table 1). Cases were heavier by an average of 5.8 lbs and were more likely to have had a family member with prostate cancer. As shown in the figure cases were less likely to report urinary symptoms, except for the final year before the diagnosis/reference date.
In crude data 58 cases (24.6%) and 126 controls (27.3%) had a screening PSA test (table 2). The overall MantelHaenszel odds ratio, adjusted for exposure observation time as well as matching and confounding variables, was 0.65 (95% confidence interval 0.45 to 0.93) in favor of screening. When the data were analyzed according to age, the odds ratio was 0.52 (0.28 to 0.98) for men 45 to 59 years old and 0.67 (0.41 to 1.09) for those 60 to 84 years old.
DISCUSSION
In this population based case-control study, we found that screening of asymptomatic men with PSA reduced their risk of metastatic prostate cancer by 35%. The effect is clinically important, especially considering that the majority of the exposed controls were screened only once. We observed a benefit of screening in men less than 60 years old as well as those 60 years old or older. The association was stronger in younger men, however the study did not have enough power to demonstrate a significant difference in effect according to age.
A number of methodological issues should be considered when interpreting the findings. Cases in this study came from a geographically defined population and controls were CASE-CONTROL STUDY OF SCREENING WITH PROSTATE SPECIFIC ANTIGEN randomly selected from the same source population. Although we may have missed some cases treated outside of the Regional Cancer Centers, such cases would have been rare. Response rates to the mailed questionnaire were 69% among the cases and 51% among the controls, ie in the range typically found in mail population surveys in North America. In a study population composed mostly of older men, almost half of them born outside Canada, such response rates seem reasonable. Medical records were obtained for 90% of the respondents (93% of the cases and 88% of the controls). Because the subjects were not informed about the study hypothesis, it seems unlikely that their participation would have been linked to PSA screening. Nevertheless, a potential for selection bias is a limitation of the study.
Our analysis included 36 cases that were asymptomatic at the time of prostate cancer diagnosis and had a positive PSA test within the preceding 6 months. While some of these cases may not have been captured by our study in the absence of screening, excluding any such cases would have increased the effect in favor of screening.
We controlled for the effect of matching by age and area of residence, as well as confounding by suspected risk or protective factors for prostate cancer and screening with digital rectal examination. We considered the possibility that men who undergo screening may be more health conscious and more likely to engage in other preventive strategies or seek medical care for any problems, and that such behaviors may protect against metastatic prostate cancer. To control for the effect of health care usage behavior, we included visits to doctors as a potential confounding variable. Confounding by unknown factors can never be ruled out in a nonrandomized study. However, such factors would have to be strongly associated with metastatic prostate cancer and PSA screening. Differences between the crude and adjusted odds ratios were primarily due to longer observation times in the cases. The main reason was a later onset of symptoms in the cases, especially in the older age group (see figure, table 2) .
Differential misclassification of PSA information in medical records seems unlikely since most of the reviews were done blindly and the abstractors followed detailed instructions. Our reliability study demonstrated excellent agreement between the abstractors. We found 96.8% agreement for having a PSA, 93.9% for a digital rectal examination and 91.1% for symptoms of prostatism. The level of agreement was also high for the coding of digital rectal examination results (96.6%) and reasons for PSA testing (90.7%).
We defined a screening (nondiagnostic) PSA test as one performed before the onset of symptoms, as recommended in the literature.
14 Although prostate related symptoms are usually associated with BPH, similar symptoms may be present in patients with prostate cancer. The dramatic increase in the frequency of symptoms just before the diagnosis of prostate cancer suggests that the inclusion of symptomatic men would have resulted in a substantial misclassification of diagnostic tests as screening. We classified PSA tests performed after a positive or suspicious DRE as diagnostic rather than screening. It is possible that some of these tests would have been done anyway for screening purposes. In 16 subjects, 15 cases and 1 control, reclassifying such tests as screening would have changed their status from unexposed to exposed. All these tests were done within 3 months of the † Urinary symptoms were defined as being bothered 10 years ago, at least "half the time," by 1 or more of symptoms of a sensation of not emptying bladder after urination, having to urinate again less than 2 hours after finishing, stopping and starting several times during urination, difficulty postponing urination, weak urinary stream, pushing or straining to begin urination or getting up to urinate during the night.
Cumulative proportion of cases and controls with prostate related symptoms before prostate cancer diagnosis/reference date.
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DRE. Additional analyses showed that in about 20% of negative DREs, a screening PSA test followed within 3 months. Applying this proportion, we performed a sensitivity analysis assuming that 3 of the 15 cases with a PSA test following a suspicious/positive DRE may have been done for screening. With this assumption the result would remain virtually unchanged (odds ratio 0.68, 0.48 to 0.97).
Previous studies offered limited evidence for the effectiveness of screening for prostate cancer. A recent case-control study by Weinmann et al produced an odds ratio of 0.70 in favor of screening with DRE and PSA. However, most of the tests were DREs and it was not possible to assess the separate effect of PSA screening. 4 In other case-control studies of screening with DRE, Friedman et al 15 and Richert-Boe et al 16 reported nonsignificant results, while Jacobsen et al 17 found a strong inverse association. In a randomized trial of PSA screening, Labrie et al reported an odds ratio of 0.31 when comparing screened and unscreened men. 10 Unfortunately only 23.1% of those randomized to screening were actually tested and an intent to screen analysis did not show a significant effect. Lu-Yao et al compared prostate cancer mortality up to 1997 among Medicare beneficiaries in the Seattle and Connecticut cancer surveillance areas. 5 Mortality rates were similar in the 2 areas although PSA testing was 5.4 times more common in Seattle. In contrast Bartsch et al demonstrated a significantly greater rate of prostate cancer mortality decrease after the introduction of mass screening with PSA in the province of Tyrol compared with the rest of Austria. 9 A number of authors used prostate cancer incidence as a surrogate for screening frequency. These studies generally found no association between increased incidence and decreases in mortality. 6Ϫ8 However, the ecological design is inherently prone to bias. Other factors, such as improved treatment of prostate cancer and risk factor changes, may contribute to mortality trends. 3 Furthermore, followup may not have been long enough in some studies. 5 
CONCLUSIONS
Although the strongest evidence for or against PSA efficacy will come from large randomized trials, the results of such trials are several years away. Moreover, generalizability of the current trials may be limited by their eligibility criteria, self-selection of participants and other design related issues. 11 Our study provides suggestive evidence for the effectiveness of screening with PSA as actually practiced in the study area in the 1990s and early 2000s. It is possible that a greater benefit would result from a screening program with regular screening intervals. Because screening for prostate cancer is a complex issue, more studies in different populations and using a variety of approaches are needed. It will be important to further delineate the effect of PSA in men with prostate related symptoms and estimate the optimal frequency of screening. While reduction in mortality and metastatic cancer are important, quality of life issues and men's preferences need to be carefully evaluated.
Cyrelle Gold reviewed medical records, and Vartouhi Jazmaji, Nicole Riley and Deva Thiruchelvam assisted with database management and data entry. † Mantel-Haenszel odds ratio stratified by exposure observation time and tertiles of the propensity score. Several variables were included in the propensity score, namely age, region, family history of prostate cancer, weight, consumption of butter and doctor visits for health problems.
